Total Payments
$23,421
2024 Payments
$5,004
Companies
100
Transactions
1,178
Medicare Patients
18,178
Medicare Billing
$5.3M
Payment Breakdown by Category
Food & Beverage$20,381 (87.0%)
Education$2,343 (10.0%)
Other$697.90 (3.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $20,381 | 1,134 | 87.0% |
| Education | $2,343 | 37 | 10.0% |
| Long term medical supply or device loan | $697.90 | 7 | 3.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,559 | 106 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,239 | 63 | $0 (2024) |
| Janssen Biotech, Inc. | $1,160 | 54 | $0 (2024) |
| Genentech USA, Inc. | $1,067 | 61 | $0 (2024) |
| Merck Sharp & Dohme LLC | $953.22 | 48 | $0 (2024) |
| Amgen Inc. | $940.52 | 49 | $0 (2024) |
| Seagen Inc. | $920.79 | 44 | $0 (2023) |
| Astellas Pharma US Inc | $881.42 | 31 | $0 (2024) |
| Lilly USA, LLC | $728.58 | 40 | $0 (2024) |
| Eisai Inc. | $725.20 | 41 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,004 | 212 | Novartis Pharmaceuticals Corporation ($1,044) |
| 2023 | $3,895 | 183 | Janssen Biotech, Inc. ($358.71) |
| 2022 | $3,161 | 169 | Seagen Inc. ($226.86) |
| 2021 | $3,378 | 177 | Novartis Pharmaceuticals Corporation ($313.76) |
| 2020 | $1,978 | 108 | AstraZeneca Pharmaceuticals LP ($259.89) |
| 2019 | $1,545 | 86 | Genentech USA, Inc. ($176.84) |
| 2018 | $2,158 | 118 | Novartis Pharmaceuticals Corporation ($243.97) |
| 2017 | $2,303 | 125 | Genentech USA, Inc. ($332.78) |
All Payment Transactions
1,178 individual payment records from CMS Open Payments — Page 1 of 48
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Incyte Corporation | PEMAZYRE (Drug), MONJUVI | Food and Beverage | Cash or cash equivalent | $18.84 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 12/20/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $31.88 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 12/19/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $20.23 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/18/2024 | Novocure Inc. | Optune (Device) | Food and Beverage | Cash or cash equivalent | $22.96 | General |
| Category: Oncology | ||||||
| 12/17/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $26.12 | General |
| Category: Oncology | ||||||
| 12/17/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $21.27 | General |
| Category: ONCOLOGY | ||||||
| 12/16/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $28.68 | General |
| 12/12/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $6.62 | General |
| Category: Oncology | ||||||
| 12/10/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $26.76 | General |
| 12/09/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $26.06 | General |
| Category: Oncology | ||||||
| 12/09/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $15.33 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $24.18 | General |
| Category: Oncology | ||||||
| 12/04/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $18.72 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $27.84 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $13.58 | General |
| Category: Oncology | ||||||
| 11/29/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $24.16 | General |
| Category: ONCOLOGY | ||||||
| 11/22/2024 | JAZZ PHARMACEUTICALS INC. | ZIIHERA (Drug) | Food and Beverage | In-kind items and services | $19.48 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/21/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | In-kind items and services | $28.97 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $26.02 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $30.92 | General |
| 11/18/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $19.26 | General |
| Category: DESMOID TUMORS | ||||||
| 11/13/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $25.67 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $11.42 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $15.35 | General |
| Category: Oncology | ||||||
| 11/11/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $8.38 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 48 | 4,386 | 211,391 | $5.7M | $2.0M |
| 2022 | 50 | 4,736 | 228,412 | $4.6M | $1.6M |
| 2021 | 50 | 4,746 | 246,631 | $3.1M | $896,002 |
| 2020 | 47 | 4,310 | 235,519 | $3.0M | $795,865 |
Total Patients
18,178
Total Services
921,953
Medicare Billing
$5.3M
Procedure Codes
195
All Medicare Procedures & Services
195 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 16 | 27,600 | $2.8M | $1.2M | 43.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 49 | 14,040 | $561,600 | $250,571 | 44.6% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 50 | 6,572 | $394,320 | $109,291 | 27.7% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 79 | 126,000 | $504,000 | $108,693 | 21.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 184 | 661 | $171,860 | $88,774 | 51.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 61 | 584 | $163,520 | $55,302 | 33.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 306 | 532 | $67,032 | $46,996 | 70.1% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 403 | 1,542 | $148,032 | $15,875 | 10.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 409 | 1,974 | $98,700 | $14,929 | 15.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 129 | 286 | $45,760 | $12,629 | 27.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 140 | 1,225 | $79,625 | $12,241 | 15.4% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 67 | 918 | $64,260 | $10,364 | 16.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 61 | 61 | $24,400 | $10,238 | 42.0% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 305 | 612 | $48,348 | $8,142 | 16.8% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 38 | 365 | $29,200 | $7,759 | 26.6% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 20 | 1,280 | $23,040 | $7,281 | 31.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 32 | 75 | $11,250 | $6,912 | 61.4% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 22 | 131 | $20,960 | $6,176 | 29.5% |
| 83550 | Iron binding capacity | Office | 2023 | 307 | 612 | $31,212 | $5,215 | 16.7% |
| 83540 | Iron level | Office | 2023 | 305 | 610 | $22,570 | $3,845 | 17.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 164 | 375 | $5,625 | $3,143 | 55.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 48 | 51 | $4,590 | $2,726 | 59.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 19 | 20 | $6,240 | $2,687 | 43.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 23 | 26 | $7,176 | $2,617 | 36.5% |
| 96361 | Infusion into a vein for hydration, each additional hour | Office | 2023 | 48 | 284 | $34,080 | $2,564 | 7.5% |
About Dr. James Mcclain, M.D
Dr. James Mcclain, M.D is a Internal Medicine healthcare provider based in Anderson, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/12/2012. The National Provider Identifier (NPI) number assigned to this provider is 1528320918.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Mcclain, M.D has received a total of $23,421 in payments from pharmaceutical and medical device companies, with $5,004 received in 2024. These payments were reported across 1,178 transactions from 100 companies. The most common payment nature is "Food and Beverage" ($20,381).
As a Medicare-enrolled provider, Mcclain has provided services to 18,178 Medicare beneficiaries, totaling 921,953 services with total Medicare billing of $5.3M. Data is available for 4 years (2020–2023), covering 195 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology, Hematology & Oncology
- Location Anderson, SC
- Active Since 06/12/2012
- Last Updated 01/28/2021
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1528320918
Products in Payments
- KISQALI (Drug) $1,162
- KEYTRUDA (Biological) $861.16
- Lenvima (Drug) $689.83
- TECENTRIQ (Biological) $577.81
- Nubeqa (Drug) $460.18
- Enhertu (Drug) $428.56
- CALQUENCE (Drug) $370.07
- TAGRISSO (Drug) $342.86
- PROMACTA (Drug) $313.07
- OPDIVO (Biological) $307.48
- CABOMETYX (Drug) $306.25
- LIBTAYO (Biological) $305.66
- ERLEADA (Drug) $293.84
- TUKYSA (Drug) $258.82
- LYNPARZA (Drug) $257.42
- VERZENIO (Drug) $257.35
- DARZALEX (Biological) $251.18
- REBLOZYL (Biological) $251.17
- PADCEV (Biological) $238.39
- JEVTANA (Drug) $236.63
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Anderson
Abhijit Raval, Md, MD
Internal Medicine — Payments: $1.9M
Internal Medicine $1.9M
Christopher Jennings, Md, MD
Internal Medicine — Payments: $1.4M
Internal Medicine $1.4M
Dr. Anita Vagnoni, Md, MD
Internal Medicine — Payments: $55,715
Internal Medicine $55,715
Dr. Carl Sofley, Md, MD
Internal Medicine — Payments: $30,357
Internal Medicine $30,357
Robert Anderson, Md, MD
Internal Medicine — Payments: $13,599
Internal Medicine $13,599
Wael Bakdash, M.d, M.D
Internal Medicine — Payments: $12,031
Internal Medicine $12,031